- Home
- AMIX vs QLGN Comparison
AMIX vs QLGN Comparison
Compare AMIX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- QLGN
- Stock Information
- Founded
- AMIX 2014
- QLGN 1996
- Country
- AMIX United States
- QLGN United States
- Employees
- AMIX N/A
- QLGN N/A
- Industry
- AMIX
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- QLGN Health Care
- Exchange
- AMIX NYSE
- QLGN Nasdaq
- Market Cap
- AMIX 3.5M
- QLGN 2.8M
- IPO Year
- AMIX N/A
- QLGN N/A
- Fundamental
- Price
- AMIX $1.41
- QLGN $3.39
- Analyst Decision
- AMIX Strong Buy
- QLGN
- Analyst Count
- AMIX 1
- QLGN 0
- Target Price
- AMIX $5.00
- QLGN N/A
- AVG Volume (30 Days)
- AMIX 2.4M
- QLGN 10.8K
- Earning Date
- AMIX 08-12-2025
- QLGN 08-13-2025
- Dividend Yield
- AMIX N/A
- QLGN N/A
- EPS Growth
- AMIX N/A
- QLGN N/A
- EPS
- AMIX N/A
- QLGN N/A
- Revenue
- AMIX N/A
- QLGN N/A
- Revenue This Year
- AMIX N/A
- QLGN N/A
- Revenue Next Year
- AMIX N/A
- QLGN N/A
- P/E Ratio
- AMIX N/A
- QLGN N/A
- Revenue Growth
- AMIX N/A
- QLGN N/A
- 52 Week Low
- AMIX $1.14
- QLGN $2.85
- 52 Week High
- AMIX $42.40
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- AMIX 47.30
- QLGN 43.88
- Support Level
- AMIX $1.32
- QLGN $3.37
- Resistance Level
- AMIX $1.59
- QLGN $3.70
- Average True Range (ATR)
- AMIX 0.20
- QLGN 0.22
- MACD
- AMIX 0.03
- QLGN -0.04
- Stochastic Oscillator
- AMIX 20.93
- QLGN 34.29
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.